Ingredients

Vitamin D3

Health Conditions77

Table of contents

Other Names

(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol7-Dehydrocholesterol, activated9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3β,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3β-olActivated 7-dehydrocholesterolArachitolCalciferolCalciolCholecalciferolCholecalciferolsColecalciferolNSC 375571Oleovitamin D3Previtamin D3Sunshine vitaminVitamin D 3

Synopsis

Vitamin D3 (Cholecalciferol): A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

Chemical Identity

Vitamin D, also known as calciferol, comprises a group of fat-soluble seco-sterols. The two primary forms of vitamin D are vitamin D2 (ergocalciferol), derived from plants and commonly used in food fortification, and vitamin D3 (cholecalciferol), synthesized in human skin from 7-dehydrocholesterol and obtained from dietary sources of animal origin. Vitamin D3's molecular formula is C₂₇H₄₄O, and it is formally classified as a secosteroid — a steroid in which one of the rings has been cleaved. Vitamin D2 and D3 differ chemically only in their side-chain structures. The D2 and D3 forms differ only in their side-chain structure; the differences do not affect metabolism (i.e., activation), and both forms function as prohormones.

Endogenous Biosynthesis

Type B UV (UVB) radiation with a wavelength of approximately 290 to 320 nanometers penetrates uncovered skin and converts cutaneous 7-dehydrocholesterol to previtamin D3, which in turn becomes vitamin D3. The UVB exposure of provitamin D3 (7-dehydrocholesterol) in the skin breaks the B-ring to form previtamin D3, which undergoes thermally induced rearrangement to vitamin D3. Season, time of day, length of day, cloud cover, smog, skin melanin content, and sunscreen are among the factors that affect UV radiation exposure and vitamin D synthesis.

Dietary Sources

Few foods naturally contain vitamin D. The flesh of fatty fish (such as trout, salmon, tuna, and mackerel) and fish liver oils are among the best sources. Beef liver, egg yolks, and cheese have small amounts of vitamin D, primarily in the form of vitamin D3 and its metabolite 25(OH)D3. Although dietary sources such as fatty fish, fish liver oil, and egg yolks contribute to vitamin D intake, they are typically insufficient to maintain optimal serum 25-hydroxyvitamin D [25(OH)D] concentrations in most individuals. Fish have the highest natural content of vitamin D, expected to derive from accumulation in the food chain originating from microalgae. Microalgae contain both vitamin D3 and provitamin D3, which suggests that vitamin D3 exists in the plant kingdom, and vitamin D3 has also been identified in several plant species.

Commercial and Supplemental Forms

Vitamin D3 is manufactured by the irradiation of 7-dehydrocholesterol from lanolin and the chemical conversion of cholesterol. Both vitamin D3 and vitamin D2 are synthesized commercially and found in dietary supplements or fortified foods. Vitamin D is found in multivitamin/multimineral supplements. It is also available in dietary supplements containing only vitamin D or vitamin D combined with a few other nutrients. Common preparation forms include softgel capsules, tablets, oral drops (particularly for infants), and chewable preparations. Pharmaceutical-grade vitamin D3 is also available as intramuscular injection formulations. Novel delivery systems—nanoemulsions, twin-screw extrusion technology, and liposomes—have been explored to overcome bioavailability and stability limitations of traditional preparations.

Vitamin D levels in the diet—from foods and supplements—are expressed in International Units (IU) but may be expressed elsewhere in micrograms (μg). The biological activity of 1 μg of vitamin D is equivalent to 40 IU.

Almost all of the U.S. milk supply is fortified with about 3 mcg (120 IU) vitamin D per cup. Many plant-based alternatives such as soy milk, almond milk, and oat milk are similarly fortified.

D3 versus D2: Comparative Potency

Vitamin D3 could be more than three times as effective as vitamin D2 in raising serum 25(OH)D concentrations and maintaining those levels for a longer time, and its metabolites have superior affinity for vitamin D-binding proteins in plasma. The two forms have traditionally been regarded as equivalent based on their ability to cure rickets, and indeed most steps involved in the metabolism and actions of vitamin D2 and vitamin D3 are identical. Firm conclusions about any different effects of these two forms of vitamin D cannot be drawn. Some studies have used dietary supplements containing the 25(OH)D3 form of vitamin D. Per equivalent microgram dose, 25(OH)D3 is three to five times as potent as vitamin D3.

2. Historical and Traditional Use

Early Recognition of Rickets

As early as the mid-1600s, Whistler and Glisson independently published scientific descriptions of rickets — caused, we now know, by vitamin D deficiency. However, neither treatise recognized the crucial role of diet or exposure to sunlight on the prevention of this disease. Rickets was a common disease in 17th-century England. Frances Glisson's treatise on rickets published in 1650, a glorious contribution to English medicine, described the clinical and anatomic features of rickets in great detail. Around 200 years later, in 1840, a Polish physician called Sniadecki realised that cases of rickets occurred in children living in the industrial centre of Warsaw but did not occur in children living in the country outside Warsaw.

Cod Liver Oil as a Traditional Remedy

Although benefits of cod liver oil as food were known as early as the seventh century, cod liver oil was only proposed as medicinal for rickets in Northern Europe at the end of the eighteenth century. The relationship between rickets and nutritional deficiency was suspected and demonstrated between 1880 and 1915, at the same time of the discovery of other vital substances (vitamins) needed to prevent beriberi, scurvy, and pellagra. By the early 19th century, physicians in Europe were advocating cod liver oil not only for rickets but also for musculoskeletal pain, joint disease, and general debility, without yet understanding its mechanism. At the turn of the 20th century, rickets was rampant among the poor children living in the industrialized and polluted northern cities of the United States.

The 20th-Century Scientific Discovery

In 1919, German researcher Kurt Huldschinsky demonstrated that ultraviolet light could cure rickets, leading to the identification of a previously unknown substance in the skin responsible for this effect. McCollum et al. correctly concluded that the factor that cures rickets is a new vitamin, which they called vitamin D. In the meantime, Huldshinsky, a physician in Vienna, and Chick et al. in England found that children suffering from rickets could be cured by exposing them to summer sunlight or artificially produced UV light. By 1922, American scientist Elmer McCollum named this nutrient vitamin D after isolating it from cod liver oil, recognizing that it was distinct from vitamin A. Steenbock and Black (1924) performed the definitive experiment when they showed that irradiation of certain foods (e.g., plant oils or yeast) increased their vitamin D activity. The biologically active form of vitamin D found in the skin, called D3, was characterized in 1936 and was shown to result from the ultraviolet radiation of 7-dehydrocholesterol. Thus vitamin D was established as a steroid.

McCollum's findings demonstrated that cod-liver oil, rich in vitamin D, could effectively prevent rickets, leading to its widespread use in medicine. The subsequent fortification of foods, especially milk, with vitamin D has resulted in the substantial decline of rickets in developed countries. With the discovery of vitamin D and the delineation of the anti-rachitic properties of cod-liver oil by the 1930s, it became possible to not only treat but also eradicate rickets in the United States.

3. Key Constituents and Metabolic Activation

The Hydroxylation Cascade

Vitamin D3 as ingested or synthesized in the skin is biologically inert and requires sequential enzymatic hydroxylation to become active. The synthesis of vitamin D into its biologically active metabolites occurs through two hydroxylation steps. The first hydroxylation takes place in the liver, where the enzyme 25-hydroxylase converts vitamin D — whether obtained through diet or sunlight — into 25-hydroxyvitamin D. The second hydroxylation occurs in the kidneys, where the enzyme 1-alpha-hydroxylase converts 25-hydroxyvitamin D into the physiologically active form. Vitamin D3 is transported to the liver where it is hydroxylated at C-25 by the enzyme 25-hydroxylase, producing 25OHD3, which is the major circulating form in vertebrates. The 25OHD3 is hydroxylated a second time at C-1 in the kidneys to the active metabolite 1,25(OH)₂D3.

In mammals, UV-B radiation from sunlight converts epidermal 7-dehydrocholesterol (provitamin D3) to vitamin D3, which is then carried by plasma proteins (e.g., vitamin D-binding protein) to the liver and converted into calcifediol or 25-hydroxyvitamin D3 via hydroxylation. Though inactive cholecalciferol is the native form, calcifediol is the clinically measured form of vitamin D3 in diagnostic tests and works as a surrogate marker of vitamin D3 levels in the human body.

The biosynthesis of active vitamin D metabolites, such as calcitriol, involves additional hydroxylation steps. These reactions are catalyzed by cytochrome P450 enzymes, which introduce hydroxyl groups at specific positions on the vitamin D molecule. The safety profile of vitamin D3 is partly attributed to the action of CYP24A1, a mitochondrial cytochrome P450 enzyme responsible for the 24-hydroxylation and catabolism of both 25(OH)D and 1,25(OH)₂D.

Vitamin D Receptor (VDR) Mechanism

Upon synthesis in the skin via ultraviolet B exposure or ingestion from dietary sources, cholecalciferol is hydroxylated in the liver and kidneys to form its active metabolite, calcitriol (1,25-dihydroxyvitamin D), which exerts pleiotropic effects through vitamin D receptor (VDR)-mediated genomic and non-genomic pathways. Calcitriol stimulates intestinal trans-epithelial transport of calcium and phosphate through both genomic and non-genomic mechanisms. The immunomodulatory effects of Vitamin D3 exhibit significant inter-individual variability, with clinical efficacy highly dependent on patient-specific factors including serum 25-hydroxyvitamin D [25(OH)D] levels and VDR gene polymorphisms.

Absorption

Both forms of vitamin D are well absorbed in the small intestine. Absorption occurs by simple passive diffusion and by a mechanism that involves intestinal membrane carrier proteins. The concurrent presence of fat in the gut enhances vitamin D absorption, but some vitamin D is absorbed even without dietary fat. Neither aging nor obesity alters vitamin D absorption from the gut.

4. Assessment of Vitamin D Status

Serum concentration of 25(OH)D is the main indicator of vitamin D status. The best method to determine the vitamin D status and, in particular, a vitamin D deficiency, is the measurement of serum 25-hydroxyvitamin D (25(OH)D), which reflects both the dietary vitamin D intake and sunlight exposure. The evaluation of vitamin D deficiency involves measuring serum levels of the 25-hydroxy form, with values below 20 ng/mL indicating deficiency and levels between 20 and 30 ng/mL suggesting insufficiency. The Institute of Medicine (IOM, U.S. National Academy of Sciences) considers the minimal 25(OH)D concentration of 20 ng/mL (50 nmol/L) as physiologically adequate for at least 97.5% of the population. There has been a controversy about what exact 25(OH)D concentrations define vitamin D deficiency and sufficiency.

High-risk populations, such as individuals with limited sun exposure, older adults, and people with malabsorption disorders, require routine screening and monitoring to ensure optimal vitamin D status. According to data from the National Health and Nutrition Examination Survey, most people in the United States consume less than the recommended amounts of vitamin D.

5. Scientific Evidence by Area of Use

5.1 Bone Health, Rickets, and Osteomalacia

The evidence for vitamin D3 in the treatment and prevention of nutritional rickets and osteomalacia is strong and historically established. The two forms have traditionally been regarded as equivalent based on their ability to cure rickets. Vitamin D3 promotes calcium absorption, which is essential for bone mineralization. Vitamin D plays a crucial role in improving calcium absorption, modulating bone remodeling, and supporting muscle function.

A dose of 400 IU/day (10 µg) of vitamin D is recommended, together with 500 mg/day of dietary calcium, for the prevention of rickets. For the treatment of nutritional rickets, 2000 IU/day (50 µg) of vitamin D should be administered for at least 3 months, together with 500 mg/day of calcium.

For osteoporosis prevention in older adults, the clinical picture is more nuanced. A meta-analysis of 11 RCTs did not find a reduced risk of any fracture (RR, 1.06; 95% CI, 0.98–1.14) or hip fracture (RR, 1.14; 95% CI, 0.98–1.32), but these trials were constrained by infrequent dosing. Combined supplementation with 800 IU of vitamin D per day and 1200 mg of calcium per day has been recommended for prevention of fractures in older adults living in institutions and in those with low vitamin D status.

Umbrella reviews of systematic reviews and meta-analyses of randomised controlled trials (RCTs) have found no evidence that supplementation with vitamin D alone reduces fracture risk. The VITAL trial (n=25,871) found that daily supplementation with 2000 IU of vitamin D3 over a median follow-up of 5.3 years had a negligible effect on fracture incidence in older men (aged ≥50 years) and women (aged ≥55 years).

High-dose bolus regimens have shown paradoxically negative effects in some studies. A yearly oral administration of 500,000 IU vitamin D of cholecalciferol (equivalent to 1400 IU/day) was harmful since it was associated with a 15% higher risk of falling. A meta-analysis including 14 RCTs found that intermittent monthly administration of vitamin D3 (over 800 IU per day equivalent) did not significantly reduce the risks of falls and fractures, with risk ratios of 1.02 (0.98–1.05) and 0.95 (0.87–1.04), respectively.

Clinical studies have shown that vitamin D supplementation, particularly when combined with resistance training or weight-bearing exercise, can significantly improve BMD, reduce fall risk, and enhance overall quality of life in osteoporotic individuals. Overall, the evidence is strongest for vitamin D3 combined with calcium in institutionalized older adults and those with confirmed deficiency; evidence for fracture reduction in the general community-dwelling population by vitamin D3 alone is not well supported by current RCT evidence.

5.2 Immune Function and Respiratory Infections

Vitamin D3 has several established roles in immunomodulation. It induces the expression of a wide range of antimicrobial peptides (AMPs), including cathelicidin and β-defensins, with broad-spectrum antimicrobial activity against bacteria, viruses, and fungi. These peptides are important for the clearance of infections and maintaining the integrity of the skin, respiratory tract, and gut mucosa. Vitamin D3 modulates the activation and function of macrophages and monocytes, which are crucial components of the innate immune system. Vitamin D3 has been reported to induce the differentiation of macrophages and to increase their capacity to phagocytose bacteria, while at the same time suppressing the production of inflammatory cytokines such as IL-6 and TNF-α.

Upon conversion to calcitriol, vitamin D3 directs adaptive immunity by adjusting T and B cell function. It favors the differentiation of regulatory T cells (Tregs) that are critical for maintaining immune tolerance and preventing autoimmune diseases.

Regarding respiratory infections specifically, a 2017 meta-analysis of data from 25 randomised controlled trials (RCTs) of vitamin D supplementation for the prevention of acute respiratory infections (ARIs) revealed a protective effect of this intervention. Observational studies have shown an inverse correlation between 25-hydroxyvitamin D levels and the occurrence of respiratory tract infections in both children and adults. The risk of confounding caused by inadequate adjustment is, however, a major limitation of observational study designs.

Clinical trials have shown that individuals with adequate Vitamin D3 levels have a lower incidence of respiratory infections, improved outcomes in autoimmune diseases, and reduced inflammation. However, the optimal dosage and long-term effects of Vitamin D3 supplementation remain areas of active investigation.

5.3 Autoimmune Disease

Research has systematically examined the immunomodulatory mechanisms of Vitamin D3 and evaluated clinical translation evidence in psoriasis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type 1 diabetes mellitus (T1DM), and inflammatory bowel disease (IBD). The dual nature of Vitamin D3 — both enhancing antimicrobial defense and suppressing excessive inflammation — represents both opportunities and challenges for clinical translation. This context-dependent immunomodulation means that therapeutic effects vary significantly across different autoimmune diseases, as evidenced by the observed efficacy differences between psoriasis (which responds well to topical treatment) and systemic diseases such as SLE and RA (where oral supplementation shows limited effects).

Vitamin D supplementation with or without omega-3 fatty acids reduced autoimmune disease by 22% in the VITAL study. This was a secondary outcome analysis and requires confirmation in prospectively designed trials focused specifically on autoimmune endpoints.

5.4 Cancer

Epidemiological and laboratory evidence has generated significant interest in the relationship between vitamin D3 status and cancer risk, but large-scale intervention trials have produced mixed results. The VITamin D and OmegA-3 TriaL (VITAL) was a nationwide, randomized, placebo-controlled, 2×2 factorial trial of vitamin D3 (cholecalciferol, 2000 IU/day) and marine omega-3 fatty acids (1 g/day) for the prevention of cancer and cardiovascular disease. There were 25,871 U.S. men aged ≥50 and women aged ≥55, including 5,106 African Americans, who participated. Primary endpoints were total invasive cancer and major cardiovascular events. Vitamin D supplementation did not reduce either of the primary endpoints.

However, secondary analyses of the VITAL data identified a potential signal for mortality: Vitamin D did not significantly reduce the primary endpoint of total invasive cancer incidence (hazard ratio [HR]=0.96 [95% CI 0.88–1.06]) but showed a promising signal for reduction in total cancer mortality (HR=0.83 [0.67–1.02]), especially in analyses that accounted for latency by excluding the first two years of follow-up (HR=0.75 [0.59–0.96]).

Many studies have depicted the protective effect of vitamin D against various cancer types through different mechanisms like controlling tumor cell survival, differentiation, proliferation, invasiveness, and metastasis. However, these are largely observational or laboratory findings, and the clinical evidence from RCTs does not yet support routine supplementation for cancer prevention in the general population.

5.5 Cardiovascular Disease

Vitamin D has garnered considerable scientific interest for its potential role in modulating cardiovascular health. Observational studies and meta-analyses have consistently reported associations between low serum 25(OH)D concentrations — typically defined as <50 nmol/L — and an increased risk of cardiovascular diseases and cardiovascular-related mortality. However, findings from large-scale randomized controlled trials (RCTs) remain inconclusive, limiting the ability to draw definitive causal inferences.

VITAL is the first large trial of moderate- or high-dose vitamin D for CVD prevention. Its null cardiovascular findings agree with the results of earlier trials. The Finnish Vitamin D Trial (FIND) was a 5-year, randomized, placebo-controlled trial among 2,495 male participants ≥60 years and post-menopausal female participants ≥65 years from a general Finnish population who were free of prior CVD or cancer. The study had 3 arms: placebo, 1600 IU/day, or 3200 IU/day vitamin D3. Taken together, current RCT evidence does not support vitamin D3 supplementation for the primary prevention of cardiovascular disease.

5.6 Diabetes and Metabolic Health

Recent observational studies have shown a potential correlation between vitamin D deficiency and cancer, cardiovascular disease, diabetes, autoimmune diseases, and depression. However, the distinction between correlation in observational studies and causation proven in RCTs is critical. High-dose vitamin D3 has demonstrated benefits in specific populations, including improved bone mineral density, immune homeostasis, glycemic control, and reduced inflammation. In patients with chronic kidney disease, cystic fibrosis, and inflammatory bowel disease, targeted supplementation has been associated with clinical improvements. Evidence for vitamin D3 improving glycemic control in type 2 diabetes remains mixed; systematic reviews have shown modest improvements in inflammatory biomarkers but inconsistent effects on HbA1c and fasting glucose.

5.7 Muscle Function and Falls in Older Adults

Vitamin D receptors are expressed in skeletal muscle tissue, and vitamin D3 is considered important for neuromuscular function. Several studies suggest that dietary supplementation with vitamin D3, in combination with calcium, reduces the risk of falls and fractures, thereby preserving mobility and preventing disability in aging populations. However, very high intermittent doses appear counterproductive. A monthly dose of 100,000 IU given over 12 months to long-term care residents with a mean age of 81 years reduced acute respiratory incidence by 40%, but was associated with a more than twofold higher rate of falls compared to a 400–1000 IU/day standard dose. This indicates that the efficacy or the potential toxicity of vitamin D supplementation depends not only on the baseline vitamin D status, but also and most importantly on the type of variable assessed.

5.8 Mortality

Numerous observational studies have shown a higher all-cause mortality with vitamin D deficiency/insufficiency, on a 25(OH)D concentration-dependent manner. Below 30 nmol/L, mortality was increased more than twofold. A nadir in the curves was found at a 25(OH)D level of around 75 nmol/L. Vitamin D3, but not vitamin D2 nor vitamin D active metabolites supplementation, was associated with a lower mortality. Vitamin D with calcium reduced mortality by 6% in a patient level pooled analysis of 70,528 patients from 8 vitamin trials. These mortality data are from observational and meta-analytic sources; causal claims require further RCT confirmation.

6. Body Systems and Health Areas of Association

Vitamin D3 and its active metabolite calcitriol interact with virtually every organ system through VDR-mediated genomic pathways. The principal associations, by body system, are summarized below.

Skeletal system: Vitamin D plays a crucial role in improving calcium absorption, modulating bone remodeling, and supporting muscle function. Established clinical role in preventing rickets, osteomalacia, and supporting bone mineral density.
Immune system: Upon conversion to calcitriol, vitamin D3 directs adaptive immunity by adjusting T and B cell function and favors the differentiation of regulatory T cells (Tregs) critical for maintaining immune tolerance and preventing autoimmune diseases.
Gastrointestinal system: In postmenopausal women, vitamin D supplementation has been shown to enhance calcium absorption in the intestines.
Renal system: The kidney is the primary site of calcitriol synthesis, and vitamin D3 status is directly linked to calcium-phosphate homeostasis. In advanced chronic kidney disease, endogenous conversion is impaired.
Cardiovascular system: Observational studies and meta-analyses have consistently reported associations between low serum 25(OH)D and an increased risk of cardiovascular diseases and cardiovascular-related mortality, though intervention trials have not demonstrated benefit.
Endocrine/metabolic system: Vitamin D undergoes a first hydroxylation in position 25 in the liver, leading to calcifediol, and a second one in position 1 in the kidney leading to calcitriol. The latter step is stimulated by PTH, IGF-I and by low calcium or phosphate intakes or concentrations.
Neuromuscular system: VDRs in muscle tissue implicate vitamin D3 in muscle strength and coordination, especially in older adults.
Dermatological system: FDA-approved indications of vitamin D3 or its derivatives include psoriasis, management of hypocalcemia, secondary hyperparathyroidism in chronic kidney disease patients, and the off-label use for vitiligo.

7. Dosage Forms and Doses Reported in Studies

Vitamin D3 is administered orally, transdermally (topical analogues), and parenterally. Doses studied in clinical research vary widely:

Institute of Medicine RDA (2010): Younger adults need 15 micrograms (mcg) or 600 International Units (IU) of vitamin D per day, and those over 70 need 20 mcg (800 IU).
Prevention of rickets: A dose of 400 IU/day (10 µg) of vitamin D is recommended, together with 500 mg/day of dietary calcium, for the prevention of rickets.
Treatment of nutritional rickets: 2000 IU/day (50 µg) of vitamin D should be administered for at least 3 months, together with 500 mg/day of calcium.
The VITAL trial: Vitamin D3 (cholecalciferol, 2000 IU/day) was administered over a median 5.3 years in a large-scale primary prevention trial.
Finnish Vitamin D Trial (FIND): The study arms used placebo, 1600 IU/day, or 3200 IU/day vitamin D3 over 5 years.
Antarctic station study: Personnel stationed in the Antarctic in winter months were given graded doses of 400, 1,000, or 2,000 IU of vitamin D3 per day for 5 months. Baseline levels of serum 25(OH)D rose from approximately 44 nmol/L to 57, 63, and 71 nmol/L, respectively.
High-dose single and intermittent regimens: Single high-dose regimens — such as 300,000 to 500,000 IU administered once — are both safe and effective, resulting in increases of serum 25(OH)D by approximately 26–28 ng/mL over 1–3 months in elderly or rheumatologic populations. Maintenance dosing with 50,000 IU weekly or 100,000 IU monthly has been shown to sustain serum 25(OH)D concentrations within the 40–60 ng/mL range, with no evidence of toxicity.
Fracture healing RCT: One trial tested a loading dose strategy (150,000 IU), and also compared low (600 IU) and high (4000 IU) daily doses of vitamin D3.
Tolerable Upper Intake Level: The safe upper limit for vitamin D is 4,000 IU/day (100 mcg/day) for children and adults 9 years and older. One microgram of cholecalciferol (D3) is the same as 40 IU of vitamin D.
Infant upper limits: The safe upper limit for vitamin D is 1,000 IU/day (25 mcg/day) for infants 0 to 6 months, and 1,500 IU/day (38 mcg/day) for infants 7 to 12 months.

8. Safety Considerations and Drug Interactions

Vitamin D Deficiency and Insufficiency

According to data from the National Health and Nutrition Examination Survey, most people in the United States consume less than the recommended amounts of vitamin D. High-risk populations, such as individuals with limited sun exposure, older adults, and people with malabsorption disorders, require routine screening and monitoring to ensure optimal vitamin D status.

Toxicity: Hypervitaminosis D

Very high levels of vitamin D in the blood (greater than 375 nmol/L or 150 ng/mL) can cause nausea, vomiting, muscle weakness, confusion, pain, loss of appetite, dehydration, excessive urination and thirst, and kidney stones. Extremely high levels of vitamin D can cause kidney failure, irregular heartbeat, and even death. High levels of vitamin D are almost always caused by consuming excessive amounts of vitamin D from dietary supplements. You cannot get too much vitamin D from sunshine because your skin limits the amount of vitamin D it makes. The Institute of Medicine (IOM) recommends an upper intake limit of 4,000 IU/day for adults to mitigate the risk of toxicity. Chronic excessive intake may lead to hypercalcemia — characterized by elevated serum calcium levels — resulting in clinical manifestations such as nausea, renal dysfunction, nephrocalcinosis, and, in severe cases, vascular calcification or cardiac arrhythmias.

Vitamin D is among the least toxic fat-soluble vitamins, and vitamin D toxicity is exceedingly rare, especially when serum calcium is monitored. The prevention and/or correction of vitamin D deficiency/insufficiency with 800–1000 IU/daily of vitamin D or 10 µg/day of calcifediol are safe. Because of their potential harm, larger doses given long-term or in intermittent regimens should not be selected without clinical supervision.

Paradoxical Effects of High-Dose Bolus Regimens

In women at high risk of fracture, annual doses of 500,000 IU of vitamin D3 increased the risk of both fractures and falls. This paradoxical effect has been observed across multiple trials with very large bolus doses. The mechanistic explanation proposed involves supraphysiological spikes in 25(OH)D causing compensatory downregulation of the VDR, but this remains under investigation.

Drug Interactions

Corticosteroid medicines, used to reduce inflammation, impair how the body handles vitamin D, which leads to lower calcium absorption and loss of bone over time. Both the weight-loss drug orlistat and the cholesterol-lowering drug cholestyramine can reduce the absorption of vitamin D and other fat-soluble vitamins (A, E, and K). Both phenobarbital and phenytoin, used to prevent and control epileptic seizures, increase the breakdown of vitamin D and reduce calcium absorption. In cases of treatment with thiazide diuretics, which decrease urinary elimination of calcium, monitoring of serum calcium concentration is recommended. In cases of treatment with drugs containing digitalis and other cardiac glycosides, the administration of vitamin D3 may increase the risk of digitalis toxicity (arrhythmia). Strict medical supervision is needed, together with serum calcium concentration and electrocardiographic monitoring if necessary.

Orlistat acts by binding the active sites of gastric and pancreatic lipases within the gastrointestinal tract to block absorption of dietary fats. As vitamin D is fat-soluble, orlistat may also inhibit dietary and supplemental vitamin D absorption. Vitamin D status should be monitored for individuals taking orlistat. If deficient, it would be prudent to recommend that these individuals take vitamin D supplements several hours prior to their orlistat dose to maximize vitamin D absorption.

Statins lower serum cholesterol concentrations by inhibiting the rate-limiting enzyme in cholesterol synthesis, HMG Co-A reductase. Vitamin D is derived from cholesterol, so by decreasing cholesterol synthesis, statins could also reduce vitamin D synthesis. Another potential mechanism for vitamin D-statin interactions is competition for CYP3A4 activity.

Populations Requiring Special Attention

More than 5,000 Black participants were included in the VITAL trial, for whom the question of the effectiveness of vitamin D is particularly relevant because their cutaneous synthesis of vitamin D in response to solar radiation is lower than that in persons in other racial or ethnic groups. Clouds, smog, old age, and having dark-colored skin reduce the amount of vitamin D your skin makes. Vitamin D supplementation resulting in 25(OH)D levels above 100 nmol/L probably increases the risk of falls and fractures. Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

References

Health Conditions

Health conditions that Vitamin D3 may help support.

AcneScientific
Vitamin D3 (cholecalciferol) is the specific form of vitamin D studied in acne clinical trials, with 1,000 IU/day associated with improvement in inflammatory acne lesions in deficient patients. It reduces sebum production, inhibits C. acnes, and modulates immune response. Deficiency is significantly more prevalent in acne patients than controls.
Allergies (Respiratory)Scientific
Vitamin D3 (cholecalciferol) is the active supplemental form of vitamin D evaluated in clinical trials for allergic rhinitis. It modulates Th1/Th2 immune balance, reduces IL-5 and IL-13, and promotes regulatory T cells. Meta-analyses confirm adjuvant vitamin D3 supplementation reduces total nasal symptom scores and IgE levels in AR patients. It is a component of clinically validated combination nutraceuticals (with quercetin and Perilla) that demonstrated 39% greater symptom improvement over standard antihistamine therapy in seasonal AR.
Andropause (Male Hormonal Aging)Scientific
Vitamin D3 (cholecalciferol) is the biologically preferred form of vitamin D, with receptors expressed in Leydig cells of the testes. A placebo-controlled RCT (Pilz et al.) demonstrated that D3 supplementation significantly increased total and free testosterone in men versus placebo over one year. Its relevance to andropause is highest in men with established vitamin D deficiency, a common finding in aging male populations.
Arterial HealthScientific
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D studied for arterial health. It inhibits the renin-angiotensin system, reduces vascular inflammation, and improves endothelial function. A 2022 network meta-analysis of 22 RCTs specifically included cholecalciferol among supplements assessed for arterial stiffness reduction.
ArthritisScientific
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, with a recognized role in bone health, chondrocyte regulation, and immune modulation relevant to OA and RA. The Arthritis Foundation lists it as studied for OA; NCCIH cites its role in bone health and immune regulation in arthritis. A 2018 meta-analysis found vitamin D3 supplementation reduced RA disease activity scores.
AsthmaScientific
Vitamin D3 (cholecalciferol) is the animal-derived form of vitamin D with well-documented roles in asthma management, including reducing exacerbation frequency and modulating Th2-driven airway inflammation. A 12-week RCT in adult asthmatics found 125 µg/day vitamin D3 significantly improved FEV1:FVC ratio vs. placebo. Meta-analyses support its adjunct role in asthma treatment.
Autoimmune ConditionsScientific
Vitamin D3 (cholecalciferol) specifically is the form most studied and used in autoimmune disease prevention and treatment. The VITAL trial used 2000 IU/day D3, reducing new autoimmune disease incidence by 22%. It regulates T-regulatory cells, suppresses adaptive immune overactivation, and VDR-mediated signaling is relevant across MS, RA, T1D, and SLE.
BackacheScientific
Vitamin D3 (cholecalciferol) is the biologically preferred form of vitamin D for supplementation in back pain. A randomized placebo-controlled trial studied 300,000 IU intramuscular vitamin D3 for discogenic pain in lumbar disc herniation. A comparative clinical trial found vitamin D3 supplementation significantly reduced VAS pain and IL-6 in adults with LBP versus untreated control, comparable to ginger extract.
Bell's PalsyScientific
Vitamin D3 (cholecalciferol) is the supplemental form used to raise serum 25-hydroxyvitamin D, which has been associated with Bell's palsy risk and severity in a 2025 systematic review and meta-analysis (BMC Neurology). As a neuro-immunomodulator, vitamin D3 may reduce facial nerve inflammation and support recovery through immune regulation and neuroprotective pathways.
Bone DensityScientific
Vitamin D3 (cholecalciferol), the animal-derived and skin-synthesized form of vitamin D, is more potent than D2 in raising serum 25(OH)D levels. RCTs consistently show that vitamin D3 combined with calcium reduces bone loss, particularly at the hip and spine, and it is endorsed by WHO, NIH, and major osteoporosis guidelines as the preferred supplemental form for bone health.
BursitisScientific
Vitamin D3 (cholecalciferol) is the biologically active form of vitamin D cited for bursitis-related inflammation. It regulates cytokines, inhibits NF-κB and prostaglandins, and correlates inversely with inflammatory markers. A meta-analysis of RCTs confirmed reduction of high-sensitivity CRP with supplementation. Cited by pain management sources for bursitis.
Carpal TunnelScientific
Vitamin D3 is the cholecalciferol form of vitamin D used in supplementation trials for CTS. Vitamin D deficiency is an independent risk factor for CTS, and several studies specifically using vitamin D3 supplementation have demonstrated improved pain, functional status, and nerve conduction in CTS patients. A 2024 RCT confirmed electroneuromyographic and clinical benefits.
Celiac DiseaseScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form used to correct vitamin D deficiency in celiac disease, as endorsed by the ACG 2013 and UK NICE 2015 guidelines. Malabsorption of fat-soluble vitamins including D3 is a hallmark of untreated CeD. Combined D3 and calcium supplementation is specifically recommended when GFD alone fails to normalize bone mineral density.
Children's AllergiesScientific
Vitamin D3 deficiency is consistently associated with increased risk of atopic dermatitis, asthma, and allergic sensitization in children. A Spanish birth cohort (n=2525) found higher child 25(OH)D3 at age 4 was associated with significantly lower odds of atopic eczema from ages 4–9 (aOR=0.90 per 5 ng/ml). Small RCTs show vitamin D3 supplementation reduces eczema severity and decreases asthma exacerbation risk in children. A 2022 systematic review and meta-analysis of pediatric RCTs evaluated vitamin D supplementation specifically in children with allergic diseases.
Children's Bone & Teeth HealthScientific
Vitamin D3 (cholecalciferol) is the most bioavailable supplemental form of vitamin D for children, more effectively raising serum 25-hydroxyvitamin D than vitamin D2. It supports calcium absorption, bone mineralization, and dental development. Studies show it is the preferred choice for correcting vitamin D deficiency in pediatric populations.
Children's Immune HealthScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D for children's immune health. Pediatric immune support protocols specifically recommend vitamin D3 year-round at 400–1,000 IU/day. D3 is more effective than D2 at raising serum 25(OH)D levels and demonstrates superior immunomodulatory activity in respiratory infection prevention trials.
Children's MultivitaminScientific
Vitamin D3 (cholecalciferol) is the preferred form of vitamin D in children's multivitamins. It is the naturally occurring, most bioavailable form, confirmed present in essentially all major branded children's MVMs (ChildLife, Kirkman, and others) per authoritative label surveys. NIH ODS-established RDA is 600 IU/day for children.
Chronic PainScientific
Vitamin D3 (cholecalciferol) is the most bioavailable and clinically studied form of vitamin D for chronic pain. RCTs show supplementation reduces pain in deficient individuals with fibromyalgia and chronic musculoskeletal pain. It suppresses neuroinflammatory cytokines TNF-α, IL-17 and modulates central pain sensitization.
Cognitive Decline & Healthy AgingScientific
Substantial observational and epidemiological evidence links low vitamin D3 status to increased risk of cognitive decline and dementia in older adults, supported by plausible neurobiological mechanisms. However, randomized controlled trials have produced largely null or mixed results, meaning supplementation has not been conclusively proven to prevent or slow cognitive decline in vitamin D-sufficient populations. The overall picture is one of an active, contested scientific relationship with promising signals but insufficient interventional proof.
Cold & FluScientific
Cholecalciferol (vitamin D3) is the primary supplemental form evaluated in respiratory infection trials. Meta-analyses including the 2017 Cochrane analysis (25 RCTs, >11,000 participants) confirm it reduces ARI risk, with greatest benefit in deficient individuals. Jolliffe et al. 2021 IPD meta-analysis (46 RCTs, >75,000 participants) confirmed benefit. It induces cathelicidin and defensins in respiratory mucosa.
ColitisScientific
Vitamin D3 (cholecalciferol) has been specifically tested in a double-blind RCT in UC patients with vitamin D deficiency, showing increased serum levels and improvements in quality of life and disease activity indices at doses of 2,000–4,000 IU/day over 90 days. VDR-mediated signaling supports intestinal barrier integrity and reduces colonic inflammation.
Concussion RecoveryScientific
Vitamin D3 (cholecalciferol) is the specific bioactive form of vitamin D that crosses the blood-brain barrier and has been evaluated in TBI and mTBI recovery clinical studies. It reduces neuroinflammation, supports BDNF expression, and correlates with improved cognitive and functional outcomes when supplemented post-TBI. The same clinical and mechanistic evidence base applying to vitamin D applies specifically to D3 as it is the predominant form administered in relevant trials.
COPDScientific
Vitamin D3 (cholecalciferol) is the directly studied form of vitamin D in COPD RCTs. An RCT in 120 COPD patients compared 50,000 IU/day vitamin D3 against calcitriol and placebo, finding clinical improvement in treated groups. A 2024 systematic review confirmed vitamin D3 supplementation improved FEV1 in COPD patients. Deficiency of D3 is strongly associated with increased exacerbation risk.
Crohn's DiseaseScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D for correcting the highly prevalent deficiency in Crohn's disease. A double-blind crossover RCT confirmed significantly raised serum vitamin D in CD patients with D3 supplementation. Clinical authorities rate it as having the strongest combined evidence (deficiency correction plus therapeutic benefit) among CD supplements.
Cushing's DiseaseScientific
Vitamin D3 (cholecalciferol) supplementation has been specifically studied in Cushing's disease patients, who have significantly higher rates of vitamin D deficiency than matched controls. A clinical study (Nutrients 2022; n=50 active CD patients) found that vitamin D deficiency severity correlated with urinary free cortisol levels. Six weeks of cholecalciferol supplementation (150,000 IU load) significantly improved insulin sensitivity, raised 25(OH)D, lowered PTH, and reduced total cholesterol in CD patients. The study recommends vitamin D supplementation as a standard part of CD management.
DepressionScientific
Vitamin D3 (cholecalciferol) is the more bioavailable form of vitamin D studied in depression clinical trials. Its deficiency is consistently linked to depressive disorders, and supplementation is recommended as a Grade A adjunct for MDD by CANMAT/WFSBP 2022 guidelines. It regulates serotonin synthesis, neuroinflammation, and HPA axis function.
DermatitisScientific
Vitamin D3 supplementation has specific RCT evidence for atopic dermatitis. A 2020 RCT in 86 children with severe AD found D3 1600 IU/day significantly reduced EASI scores versus placebo. A 2024 meta-analysis of 11 RCTs confirmed overall significant reduction in AD severity with vitamin D supplementation.
Dry EyesScientific
A meta-analysis of 14 studies found serum 25(OH)D3 significantly lower in DED patients versus controls (WMD −5.93; p<0.001). Clinical trials show vitamin D3 supplementation improves TBUT, Schirmer, and OSDI. When combined with lutein, zeaxanthin, and curcumin in an 8-week RCT (n=155), it met primary DED endpoints (p<0.001 both measures).
EczemaScientific
Vitamin D3 (cholecalciferol) is the form of vitamin D most studied in atopic dermatitis, with a meta-analysis of nine RCTs demonstrating significant SCORAD improvement. It modulates filaggrin expression, Th2 immune dysregulation, and antimicrobial peptide production—all central to eczema pathogenesis.
Fertility (Women's)Scientific
Vitamin D3 (cholecalciferol) is the most bioavailable supplemental form of vitamin D. Low vitamin D3 is associated with impaired oocyte quality, reduced ovarian reserve, and poorer IVF outcomes. An RCT combining vitamin D3 with myo-inositol, folic acid, and melatonin significantly improved IVF clinical pregnancy rates (42% vs. 24%).
FibromyalgiaScientific
Vitamin D3 (cholecalciferol) is the form most commonly used in clinical studies evaluating vitamin D supplementation for FM. Evidence base is the same as for vitamin D: meta-analyses confirm association of deficiency with FM symptom severity and significant pain reduction with supplementation in deficient patients. The 2025 systematic review and meta-analysis found significant FM pain reduction (SMD −0.85 to −0.87) with vitamin D supplementation.
Flexibility & MobilityScientific
Vitamin D3 (cholecalciferol) is the more bioavailable form of vitamin D, essential for musculoskeletal health, chondrocyte function, and muscle physiology relevant to joint mobility. Deficiency correlates with worsened OA outcomes and impaired physical function. A 2025 network meta-analysis of 39 RCTs for knee OA included vitamin D among evaluated supplements, and supplementation improves muscle strength and physical performance tests.
Focus & Attention (Children's)Scientific
Vitamin D3 (cholecalciferol) is the biologically active form studied in ADHD pediatric research. Multiple studies document lower vitamin D3-related serum markers in children with ADHD. RCTs demonstrate improvement in attention and hyperactivity with D3 supplementation. A 2024 network meta-analysis of 48 ADHD pediatric studies (n=3,650) ranked vitamin D among the most effective nutritional interventions.
Gum Health (Periodontal)Scientific
Vitamin D3 (cholecalciferol) is the more bioavailable form of vitamin D evaluated in RCTs for periodontal disease as an adjunct to periodontal therapy. Clinical trials evaluating specific vitamin D doses (500–2000 IU/day) have predominantly used cholecalciferol. Its bone-protective, anti-inflammatory, and immunomodulatory properties are directly relevant to alveolar bone preservation and periodontal inflammation control.
Hair Growth & ThicknessScientific
Vitamin D3 (cholecalciferol) is the active supplemental form linked to hair follicle cycling via VDR signaling in dermal papilla and keratinocytes. Deficiency is associated with multiple forms of alopecia, and correcting deficiency supports hair follicle anagen initiation. Clinical evidence parallels that of vitamin D, as D3 is the predominant supplement form studied.
Hair LossScientific
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, acting via follicular vitamin D receptors to regulate hair cycling. Deficiency is associated with alopecia areata and androgenetic alopecia. Clinical guidelines recommend correction of documented deficiency in patients with non-scarring hair loss.
Healthy AgingScientific
Vitamin D3 (cholecalciferol) is the most bioavailable and biologically active form of supplemental vitamin D, with the VITAL trial (n=25,871, 2000 IU/day, 5.3 years) demonstrating reduced cancer mortality and autoimmune disease. It is linked to telomere protection, immune aging support, bone density maintenance, and reduced all-cause mortality in older adults.
Healthy Growth & DevelopmentScientific
Vitamin D3 (cholecalciferol) is the animal-derived, most bioavailable form of vitamin D, synthesized in the skin by UV-B radiation and used in most clinical supplementation trials in children. It is the preferred form in pediatric supplementation guidelines (AAP, EFSA) specifically because it is more effective than D2 at raising serum 25(OH)D. Its role in bone growth, calcium homeostasis, and the GH/IGF-1 axis firmly establishes it as a critical nutrient for healthy childhood growth and development.
Hearing HealthScientific
Vitamin D3 (cholecalciferol) is the preferred form of vitamin D for supplementation and shares the same hearing-health evidence base as vitamin D generally. Deficiency correlates with higher hearing loss risk, increased tinnitus loudness, and worse outcomes in sudden SNHL. Correcting deficiency with D3 has shown clinical benefit for tinnitus in RCTs.
Heart HealthScientific
Vitamin D3 has an extensively studied relationship with cardiovascular health, supported by substantial epidemiological, mechanistic, and clinical trial data. Observational studies consistently link low vitamin D levels to higher risks of hypertension, atherosclerosis, heart failure, and myocardial infarction. Mechanistically, vitamin D3 modulates the renin–angiotensin system, endothelial function, inflammation, and cardiomyocyte calcium handling. However, large RCTs have generally not confirmed a significant reduction in major cardiovascular events with supplementation in unselected populations, and evidence strength remains mixed.
Hypothyroid & Hashimoto'sScientific
Cholecalciferol (vitamin D3) is the most clinically effective form of vitamin D for reducing thyroid autoantibodies in Hashimoto's thyroiditis. A 2021 meta-analysis confirmed that vitamin D3 specifically (not generic vitamin D) significantly reduced TPOAb titers (SMD −1.48; p=0.006) in HT patients. It works by modulating Treg/Th17 immune balance and reducing pro-inflammatory cytokines.
IBSScientific
Vitamin D3 has IBS-specific RCT and meta-analytic evidence. A 2025 umbrella review (Nutr Rev, 175 RCTs) identified vitamin D3 as improving IBS symptom severity. An RCT in 74 IBS-D patients with vitamin D deficiency found significant IBS symptom severity and IL-6 reduction with 50,000 IU/week for 9 weeks versus placebo. Vitamin D deficiency is disproportionately prevalent in IBS patients.
Inflammatory Bowel Disease (IBD)Scientific
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D and is specifically studied in IBD clinical trials. Deficiency is prevalent in IBD patients and associated with disease activity; D3 supplementation reduces inflammatory markers and may maintain CD remission in clinical trials.
Keratosis PilarisScientific
Vitamin D3 derivatives are listed in StatPearls as a recognized treatment escalation option for KP beyond first-line keratolytics, for patients who do not respond to initial therapy. This is mechanistically supported by vitamin D3's role in regulating keratinocyte differentiation relevant to KP's follicular hyperkeratosis pathology.
Leaky GutScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D with documented effects on intestinal barrier function via VDR-mediated tight junction protein upregulation. A Mayo Clinic RCT (NCT01640496) specifically studied vitamin D3's effects on colonic permeability and mucosal tight junction protein expression in ulcerative colitis. Multiple authoritative gut health reviews identify vitamin D3 as one of the top evidence-supported supplements for intestinal barrier support.
Macular DegenerationScientific
Vitamin D3 (cholecalciferol) is the specific form of vitamin D studied in AMD research and included in AMD clinical trial supplement formulations. Observational studies associate adequate vitamin D3 status with lower AMD risk, and a Japanese case-control study linked low vitamin D intake to neovascular AMD. Vitamin D3 at 2000 IU/day was included in the AMD-specific multivitamin RCT (NCT03946085). Its anti-inflammatory and anti-VEGF properties are mechanistically relevant to AMD.
Male Pattern Hair LossScientific
Vitamin D3 regulates hair follicle cycling via vitamin D receptor (VDR) signaling; VDR mutations cause alopecia. A 2024 systematic review (PubMed 39440586, 49 studies) identified vitamin D as one of four critical micronutrients whose deficiency is consistently associated with AGA risk and whose supplementation shows potential benefit for hair growth.
Mast Cell ActivationScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D, with evidence for mast cell stabilization via VDR-dependent suppression of IgE-mediated degranulation. A 2016 PubMed study confirmed VDR signaling is required for mast cell stability, and deficiency causes activation. D3 raises serum 25(OH)D more effectively than D2, making it the clinically recommended form for MCAS-related vitamin D protocols.
MenopauseScientific
Vitamin D3 (cholecalciferol) is the most bioavailable supplemental form of vitamin D, directly relevant to postmenopausal bone health and osteoporosis prevention. A 2025 systematic review confirmed its benefits alongside calcium for postmenopausal osteoporosis management. Postmenopausal women are specifically identified as a population at high risk for vitamin D deficiency.
Metabolic SyndromeScientific
Substantial clinical and epidemiological evidence links vitamin D3 deficiency to metabolic syndrome (MetS), with observational meta-analyses consistently showing an inverse association between serum 25(OH)D and MetS risk. Randomized controlled trials (RCTs) and their meta-analyses suggest vitamin D3 supplementation may modestly reduce fasting glucose, triglycerides, and insulin resistance, particularly in deficient individuals. However, causality remains contested: some meta-analyses find no significant improvement in metabolic parameters, leaving the observed association partly attributable to confounding. The evidence base is scientific but the therapeutic benefit is not firmly established.
Mitochondrial HealthScientific
Vitamin D receptors are present in mitochondrial membranes, and vitamin D deficiency impairs mitochondrial ATP production and respiratory chain activity. Evidence shows vitamin D modulates mitochondrial function through regulation of mitochondrial fission/fusion dynamics and ROS production, with deficiency linked to widespread mitochondrial dysfunction.
Muscle RecoveryScientific
Vitamin D3 (cholecalciferol) is the most bioavailable form of supplemental vitamin D and three times more potent than D2 at raising serum 25(OH)D. It has documented roles in skeletal muscle VDR signaling, inflammation modulation, and calcium handling, with indirect evidence supporting recovery in deficient athletes.
Myasthenia GravisScientific
Vitamin D3 (cholecalciferol) is the specific form studied in MG clinical investigations. A pilot study of 800 IU/day vitamin D3 in 13 MG patients showed 22% increases in serum levels and 38% muscle fatigue improvement. Vitamin D3 appears to regulate Treg cells in MG patients, and its deficiency is consistently associated with MG prevalence across cohort and cross-sectional studies.
Osteoporosis PreventionScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D for osteoporosis prevention, more potent at raising serum 25(OH)D than D2. It is universally included in osteoporosis management guidelines. RCTs confirm its role, especially when combined with calcium, in increasing BMD and reducing fracture risk in older adults.
Overactive BladderScientific
Vitamin D3 (cholecalciferol) is the primary supplemental form studied in relation to overactive bladder and urinary incontinence. A meta-analysis found vitamin D deficiency increased OAB risk more than 4-fold, and supplementation reduced urinary incontinence risk by 66%. Vitamin D3 receptors exist in bladder muscle and pelvic floor tissue, and correcting deficiency has shown clinical urinary symptom improvements.
Parkinson's DiseaseScientific
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, with consistent evidence of deficiency in Parkinson's disease patients. Observational studies link higher serum 25(OH)D3 levels with lower PD incidence. Small RCTs of D3 supplementation have been conducted in PD with modest motor improvement signals.
PerimenopauseScientific
Vitamin D3 (cholecalciferol) is the preferred, most bioavailable form of vitamin D for supplementation and is specifically used in perimenopausal care for bone health, mood, immune function, and overall hormone regulation during the menopausal transition. European Menopause Society guidelines support its use.
Picky Eater NutritionScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D and is specifically recommended for picky eaters deficient in vitamin D due to avoidance of dairy and fatty fish. It is more effective than D2 at raising serum 25-hydroxyvitamin D levels. Children's multivitamins for picky eaters commonly include D3.
Post-Illness RecoveryScientific
The most biologically active supplemental form of vitamin D, vitamin D3 (cholecalciferol) is the form used in the majority of clinical trials demonstrating immune modulation and reduced risk and duration of respiratory illness. It specifically supports post-illness immune restoration by upregulating antimicrobial peptides and modulating T-cell responses.
Post-Viral RecoveryScientific
Cholecalciferol (vitamin D3) is the most bioavailable supplemental form of vitamin D and is specifically studied in COVID-19 and post-viral recovery contexts. It supports immune modulation and reduces inflammatory markers. Clinical protocols for long COVID from the VA and published integrative medicine reviews recommend vitamin D3 as part of post-viral recovery.
Postnatal & Postpartum RecoveryScientific
Vitamin D3 (cholecalciferol) is the preferred form of vitamin D in postnatal supplements, shown in RCTs to correct postpartum maternal and infant deficiency when taken at 6,000 IU/day. It supports immune recovery, bone health, mood stability, and breastmilk vitamin D content. Breastfeeding women face heightened risk of deficiency due to transfer of D3 into milk.
Prenatal HealthScientific
Vitamin D3 (cholecalciferol) is the most bioavailable and clinically preferred form of vitamin D for prenatal supplementation, demonstrating superior ability to raise serum 25(OH)D levels compared to D2. Used in the majority of prenatal RCTs, it supports fetal skeletal development, reduces preeclampsia risk, and supports neonatal immune and neurodevelopmental outcomes. ACOG and NICE specifically reference vitamin D3 in their prenatal supplementation contexts.
PsoriasisScientific
Vitamin D3 (cholecalciferol) and its analogue calcipotriol are established in the treatment of psoriasis. Calcipotriol is a first-line topical therapy. Oral vitamin D3 supplementation has been evaluated in RCTs including a randomized double-blind placebo-controlled trial for chronic plaque psoriasis published in J Dermatolog Treat (2018), with a 2023 meta-analysis of RCTs showing PASI improvement.
Rashes and HivesScientific
Vitamin D3 (cholecalciferol) is the supplemental form most frequently studied in chronic urticaria RCTs. A 2025 systematic review confirms that interventional studies using D3 supplementation demonstrated symptom improvement and reduced disease severity in chronic urticaria. Its mechanism involves mast cell stabilization and reduction of histamine-driven inflammation.
Rheumatoid ArthritisScientific
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D, with superior efficacy over D2 for raising serum 25(OH)D. It suppresses Th17-driven RA inflammation and promotes regulatory T cells. Multiple RCTs of vitamin D3 supplementation in RA patients show improvements in DAS28, pain, and inflammatory markers.
SciaticaScientific
Vitamin D3 (cholecalciferol) is the bioactive supplemental form of vitamin D, identified in multiple authoritative clinical reviews as a key nutrient for sciatic nerve pain. It reduces neuroinflammation, supports myelin health, and addresses deficiency linked to worsening sciatica. A randomized clinical trial used D3 in a combination treatment for discogenic sciatica.
ScoliosisScientific
Multiple peer-reviewed studies and meta-analyses show that vitamin D deficiency is significantly prevalent in adolescent idiopathic scoliosis (AIS) patients, negatively correlating with bone mineral density and positively correlating with Cobb angle severity. A 2023 meta-analysis (6 studies, 1,428 patients) found vitamin D insufficiency in ~36% and deficiency in ~41% of AIS patients. A Romanian randomized interventional trial (2017–2020) demonstrated that daily supplementation with vitamin D (2,000 IU), calcium, and melatonin positively affected curve progression in children aged 7–16 with idiopathic scoliosis.
Seasonal Mood SupportScientific
Vitamin D3 (cholecalciferol) is the endogenous form of vitamin D produced in skin via UVB and the primary supplemental form studied for SAD. Reduced winter sunlight causes declining vitamin D3 production, and low serum 25(OH)D is consistently associated with SAD. Clinical evidence parallels that for vitamin D broadly: mixed results across RCTs, with NCCIH not currently supporting D3 monotherapy as an effective SAD treatment.
Seasonal Respiratory HealthScientific
Vitamin D3 plays an immunomodulatory role in respiratory allergy, with epidemiological evidence linking deficiency to increased allergic rhinitis severity and a dedicated clinical trial (Bakhshaee et al., Eur Arch Oto-Rhino-Laryngol, 2019) showing supplementation improved AR symptoms. It promotes Treg development, suppresses Th2 polarization, and reduces IgE production.
Sleep ApneaScientific
Vitamin D3 (cholecalciferol) is the primary form studied in relation to OSA. Meta-analyses (29 studies, N=6,717) confirm lower 25(OH)D in OSA patients, with severity inversely correlated with vitamin D status. Sustained deficiency is associated with a 25–28% increased hazard for developing OSA in a large retrospective cohort. Mechanistically, vitamin D3 may support upper airway dilator muscle function and reduce OSA-associated inflammation.
TestosteroneScientific
Vitamin D3 (cholecalciferol) is the primary supplemental form of vitamin D studied in testosterone RCTs. It acts via Leydig cell vitamin D receptors to stimulate testosterone synthesis and reduce SHBG. A 12-month double-blind RCT found supplementation with approximately 3,300 IU/day significantly increased total and free testosterone versus placebo in vitamin D-insufficient men.
TMJScientific
Vitamin D3 (cholecalciferol) is the specific form studied in a double-blind RCT for vitamin D-deficient TMD patients in combination with splint therapy, showing significant improvements in mouth opening and pain scores. It was also included in a TMD nutraceutical RCT formulation (Boswellia, magnesium, tryptophan, B2, D3). Deficiency is associated with higher TMD incidence in cohort studies.
Tooth RemineralizationScientific
Vitamin D3 (cholecalciferol) is the active supplemental form of vitamin D, supporting calcium absorption and regulating mineral homeostasis required for enamel remineralization. Evidence links adequate D3 status to reduced caries risk and improved enamel mineralization, with D3 receptors identified on ameloblasts and odontoblasts.
Upper Respiratory HealthScientific
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D used in URTI clinical research. The landmark 2017 BMJ meta-analysis (25 RCTs, n=11,321) found D3 supplementation significantly reduced acute respiratory infection incidence, with greatest benefit in severely deficient individuals using daily/weekly dosing.
Vertigo & BalanceScientific
Vitamin D3 deficiency is associated with increased occurrence and recurrence of benign paroxysmal positional vertigo (BPPV). A landmark multicenter RCT (Jeong et al., 2020, Neurology, n=1050) demonstrated vitamin D3 400 IU plus calcium carbonate 500 mg twice daily for 1 year significantly reduced BPPV annual recurrence rate (IRR 0.76, p<0.001). A meta-analysis of five studies confirmed significant BPPV recurrence reduction (fixed-effects RR=0.68, p<0.0001) with vitamin D supplementation.
Viral Immune ResponseScientific
Vitamin D3 (cholecalciferol) is the most biologically active supplemental form of vitamin D, with established roles in modulating both innate and adaptive antiviral immune responses. Clinical evidence supports its role in reducing respiratory viral infection risk, particularly in deficient individuals. It induces cathelicidins and defensins and modulates T cell responses.
VitiligoScientific
Vitamin D3 deficiency is significantly more common in vitiligo patients, confirmed by multiple meta-analyses. It promotes melanocyte tyrosinase activity and differentiation via melanocyte vitamin D receptors and has immunomodulatory effects on autoreactive T cells. High-dose supplementation (35,000 IU/day) produced significant repigmentation in a published case series, and expert dermatologists recommend repletion when levels are insufficient.

Body Systems

Body systems that Vitamin D3 may help support.

No body systems available.